

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	2285205
<b>Application Number:</b>	10666689
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	2217
<b>Title of Invention:</b>	Human PF4A receptors, nucleic acid encoding and antibodies binding thereto
<b>First Named Inventor/Applicant Name:</b>	James Lee
<b>Customer Number:</b>	9157
<b>Filer:</b>	Craig G. Svoboda/Barbara Hebert
<b>Filer Authorized By:</b>	Craig G. Svoboda
<b>Attorney Docket Number:</b>	P0706P2C2D2C1
<b>Receipt Date:</b>	05-OCT-2007
<b>Filing Date:</b>	19-SEP-2003
<b>Time Stamp:</b>	14:56:02
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 1050
RAM confirmation Number	162
Deposit Account	070630

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:  
Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	P0706P2C2D2C1_Request_for_RCE.pdf	235378 c7b2c99baf8b464b9a7a4d3a78529c73a71382	no	8
<b>Warnings:</b>					
This is not a USPTO supplied RCE SB30 form.					
<b>Information:</b>					
2	Miscellaneous Incoming Letter	P0706P2C2D2C1_Second_Decl_James_Lee.pdf	161398 599b7d5193a6ba574b650a4341561138b1256c22	no	4
<b>Warnings:</b>					
<b>Information:</b>					
3	Extension of Time	P0706P2C2D2C1_Ext_of_Time.pdf	59859 a1d876c19b4c8b4d591a45c2448a29c0184d1	no	1
<b>Warnings:</b>					
<b>Information:</b>					
4	Information Disclosure Statement (IDS) Filed	P0706P2C2D2C1_IDS_Statement.pdf	153761 1e42230e4b7056dc2ff4e03edc168a0625066d	no	4
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
5	NPL Documents	P0706P2C2D2C1_Seaver_Gen_Eng_August_1994.pdf	303092 aa15cb3ede4ed1b0f4e1d5b992b4d0291b0ed301	no	2
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	P0706P2C2D2C1_Shadidi_Biodrugs_18_3_pp181_187_2004.pdf	712247 d03e9bdf9c338f0bc0855da10395713c7a3c9c98	no	7
<b>Warnings:</b>					
<b>Information:</b>					
7	Fee Worksheet (PTO-06)	fee-info.pdf	8177 8b2a70907d51172977a3a34b35e41fb4baxef91d	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			1633912		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.